Kirilys Therapeutics launches, completes seed financing round

By The Science Advisory Board staff writers

March 28, 2022 -- Kirilys Therapeutics, a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, has announced that it completed a seed financing led by Lightspeed Venture Partners.

Kirilys Therapeutics also said that it licensed KRLS-017, its lead compound, from Ube Industries. The company said the financing round will enable Kirilys to complete all activities through the Investigational New Drug filing of KRLS-017, as well as preparatory work for the phase I clinical development program.

KRLS-017, a reversible small molecule inhibitor of cyclin dependent kinase 7 (CDK7), showed selectivity and antitumor efficacy along with very favorable properties for an oral drug, Kirily's said.

Finally, the company reported that it also completed a partnership agreement with D2G Oncology, which uses genetically defined animal tumor models to reveal relationships between cancer genotypes and drug efficacy.


Copyright © 2022 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter